Evidence map›Paper›PMID 36512081›Full record

ReviewAnnals of hematology2023

Anti-CD30 antibody-drug conjugate therapy in lymphoma: current knowledge, remaining controversies, and future perspectives.

H Miles Prince, Martin Hutchings, Eva Domingo-Domenech, Dennis A Eichenauer, Ranjana Advani

Open access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Annals of hematology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 2 pooled it
4.1field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 2 syntheses or guidelines pooled it, 31 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025
    Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 5 institutions in 5 countries.

H Miles PrinceSir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, VIC, Australia. miles.prince@petermac.org.
Martin HutchingsDepartment of Haematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
Eva Domingo-DomenechDepartment of Hematology, Institut Catala D'Oncologia, Institut de Reserca IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain.
Dennis A EichenauerFirst Department of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf, University of Cologne, Cologne, Germany.
Ranjana AdvaniDepartment of Medicine, Division of Oncology, Stanford University, Stanford, CA, USA.
Institut d'Investigació Biomédica de Bellvitge · ESRigshospitalet · DKStanford University · USUniversity Hospital Cologne · DEUniversity of Melbourne · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

CD30 is overexpressed in several lymphoma types, including classic Hodgkin lymphoma (cHL), some peripheral T-cell lymphomas (PTCL), and some cutaneous T-cell lymphomas. The antibody-drug conjugate brentuximab vedotin targets CD30-positive cells and has been evaluated for the treatment of various lymphoma entities. This narrative review summarizes 10 years of experience with brentuximab vedotin for the treatment of CD30-positive lymphomas, discusses novel therapies targeting CD30 in development, and highlights remaining controversies relating to CD30-targeted therapy across lymphoma types. The collective body of evidence for brentuximab vedotin demonstrates that exploitation of CD30 can provide sustained benefits across a range of different CD30-positive lymphomas, in both clinical trials and real-world settings. Preliminary experience with brentuximab vedotin in combination with immune checkpoint inhibitors for relapsed/refractory cHL is encouraging, but further exploration is required. The optimal use of brentuximab vedotin for first-line therapy of PTCL remains to be determined. Further research is required on brentuximab vedotin treatment in high-risk patient populations, and in rare lymphoma subtypes, for which no standard of care exists. Novel therapies targeting CD30 include chimeric antigen receptor therapies and bispecific antibody T-cell engagers, which may be expected to further improve outcomes for patients with CD30-positive lymphomas in the coming years.

Indexed as

Antineoplastic AgentsHodgkin DiseaseImmunoconjugatesLymphoma, T-Cell, CutaneousLymphoma, T-Cell, PeripheralSkin NeoplasmsBrentuximab VedotinHumansKi-1 AntigenAntineoplastic AgentsBrentuximab VedotinImmunoconjugatesKi-1 AntigenAntibody–drug conjugateBrentuximab vedotinCD30 expressionClassic Hodgkin lymphomaCutaneous T-cell lymphomaPeripheral T-cell lymphoma

Identifiers

PMID36512081
PMCPMC9807535
OpenAlexW4311282970

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.